ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rescue Medications

Its studies are mostly in Lung Neoplasms · Esophageal Neoplasms, led by Merck.

Furthest: phase 2, since May 31, 20242 company-led studies, 2 open or runningNext primary completion: May 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck22 open or runningphase 2since May 31, 2024May 31, 2024May 9, 2028phase 2 · NCT06445972

Also a collaborator on its studies: Daiichi Sankyo.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2024First study: phase 2 study in Esophageal NeoplasmsFirst studyNCT06445972 · 210 planned · United States, Brazil, Chile and more
  2. Jan 13, 2025Phase 2 study in Lung NeoplasmsNCT06780098 · 144 planned · United States, Chile, China and more

Ahead

  1. May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsNCT06445972
  2. Mar 2, 2032Primary completion: phase 2 study in Lung NeoplasmsNCT06780098

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06780098Lung Neoplasms · United States, Chile, China and more2RecruitingMar 2, 2032144
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMay 9, 2028210

How it is read

Names in the registry

  • “Rescue Medications”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.